Role of the Osteochondral Unit in the Pathogenesis of Osteoarthritis: Focus on the Potential Use of Clodronate

Curr Rheumatol Rev. 2022;18(1):2-11. doi: 10.2174/1573397117666211006094117.

Abstract

Osteoarthritis (OA) is a chronic disease characterized by inflammation and progressive deterioration of the joint. The etiology of OA includes genetic, phlogistic, dismetabolic and mechanical factors. Historically, cartilage was considered the target of the disease and therapy was aimed at protecting and lubricating the articular cartilage. The osteochondral unit is composed of articular cartilage, calcified cartilage, and subchondral and trabecular bone, which work synergistically to support the functional loading of the joint. Numerous studies today show that OA involves the osteochondral unit, with the participation therefore of the bone in the starting and progression of the disease, which is associated with chondropathy. Cytokines involved in the process leading to cartilage damage are also mediators of subchondral bone edema. Therefore, OA therapy must be based on the use of painkillers and bisphosphonates for both the control of osteometabolic damage and its analgesic activity. Monitoring of the disease of the osteochondral unit must be extensive, since bone marrow edema can be considered as a marker of the evolution of OA. In the present review, we discuss some of the pathogenetic mechanisms associated with osteoarthritis, with a particular focus on the osteochondral unit and the use of clodronate.

Keywords: Osteoarthritis; bisphosphonates; bone marrow edema; clodronate; joint prosthesis; osteochondral unit; rehabilitation.

Publication types

  • Review

MeSH terms

  • Bone and Bones / pathology
  • Cartilage, Articular*
  • Clodronic Acid / therapeutic use
  • Humans
  • Inflammation / pathology
  • Osteoarthritis* / pathology

Substances

  • Clodronic Acid